Methods and formulations for modulating Lyn kinase activity and treating related disorders

Details for Australian Patent Application No. 2006283211 (hide)

Owner Melior Pharmaceuticals I, Inc.

Inventors Reaume, Andrew; Saporito, Michael S.

Agent FB Rice

Pub. Number AU-B-2006283211

PCT Pub. Number WO2007/024863

Priority 60/709,798 22.08.05 US; 60/808,533 26.05.06 US

Filing date 22 August 2006

Wipo publication date 1 March 2007

Acceptance publication date 21 June 2012

International Classifications

A61K 31/495 - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 3/04 Drugs for disorders of the metabolism

Event Publications

20 March 2008 PCT application entered the National Phase

  PCT publication WO2007/024863 Priority application(s): WO2007/024863

28 October 2010 Assignment before Grant

  Melior Discovery, Inc. The application has been assigned to Melior Pharmaceuticals I, Inc.

21 June 2012 Application Accepted

  Published as AU-B-2006283211

18 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006283215-Methods of applying antimicrobial formulations on food

2006283208-Sulfonamides